Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex to Shorten Time-to-extubation Among Postoperative ICU Patients Following AVR, CABG Surgery, or AVR/CABG Surgery
NCT03196167Phase 4Completed
- Sponsor
- Yale University
- Start
- May 2017
- Primary completion
- Oct 2020
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in neuromuscular blockade (NMB) comparing Sugammadex with Placebo (2 arms). Primary endpoint: Time to Extubation up to 2 weeks. Started May 2017; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03196167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196167.